Kythera Prices $125M Offering After Double-Chin Drug OK'd
Kythera Biopharmaceuticals Inc. said Tuesday it will raise just over $125 million in a public share offering, just days after its lead drug candidate to treat double chins received unanimous approval...To view the full article, register now.
Already a subscriber? Click here to view full article